Aktienanalyse zu Pasithea Therapeutics Corp (KTTA)KTTAPasithea Therapeutics Corp

Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Pasithea Therapeutics Corp (KTTA) is a good buy right now due to its recent price increase of 55.51% over the last 5 days and the positive momentum indicated by an RSI of 81.843, suggesting strong buying pressure. The company has also received FDA clearance for its PAS-004 candidate, which could significantly enhance its market position in treating NF1-associated tumors. However, it is important to note that the company has a negative net income of -5,273,852 USD in Q2 2026, which poses a risk to its financial stability.